Introduction
============

Of all breast and ovarian cancers, 5--10% are due to genetic predisposition \[[@B1]\]. Mutations in the two high penetrance genes *BRCA1*and *BRCA2*are well known, but they account for only 20--30% of the familial aggregation of breast cancer. The remaining cases could be the result of a few additional, yet unidentified, high penetrance mutations, but the polygenic model may provide a more plausible explanation \[[@B2]\]. According to this model, genetic susceptibility to breast cancer is due to several loci, each conferring a modest independent risk \[[@B3]\]. Because the protein products of the genes thus far associated with breast and/or ovarian cancer predisposition are central players in the pathways involved in cell cycle checkpoint functions, and in the sensing, transduction and repair of DNA lesions \[[@B4]\], other similarly acting genes may represent new potential candidates.

The ATR (ataxia-telangiectasia- and Rad3-related) kinase is essential for the maintenance of genomic integrity. It is a key activator of the cellular responses to DNA lesions \[[@B5]\]. In response to DNA double-strand breaks induced by ionizing radiation ATR, along with ATR-interacting protein, acts in parallel with ATM (ataxia-telangiectasia mutated), which is defective in the neurodegenerative disorder ataxia-telangiectasia and is also associated with breast cancer susceptibility \[[@B6]-[@B9]\]. Whereas ATM is responsible for the immediate and rapid response to double-strand breaks, ATR joins in later and maintains the phosphorylated state of specific substrates. However, this is not the main role played by ATR; it also responds to ultraviolet-induced lesions, stalled replication forks and hypoxia \[[@B5]\]. In response to these events, ATR phosphorylates key proteins in various branches of the DNA damage response pathways, such as p53, BRCA1, CHK1 and Rad17, thereby activating DNA repair, cell cycle checkpoints, or apoptosis \[[@B10],[@B11]\].

The cellular functions of ATR are indispensable, as demonstrated in mice, in which biallelic disruption of *ATR*leads to early embryonic lethality. In contrast, *ATR*^+/-^mice exhibit only a small decrease in survival but tumor incidence is increased \[[@B12]\]. In humans a connection between *ATR*defects and tumorigenesis has also been suggested, mainly by studies reporting somatic changes in *ATR*in gastric and endometrial cancers exhibiting microsatellite instability \[[@B13],[@B14]\]. Consequently, it has been proposed that *ATR*serves as a haploinsufficient tumour suppressor on a mismatch repair deficient background \[[@B15]\].

Recently, inherited defects in ATR signalling were shown to associate with Seckel syndrome, because patients in two families were found to be homozygous for a hypomorphic *ATR*mutation. Seckel syndrome is a heterogenous recessive disorder that is characterized by dwarfism, developmental delay and severe microcephaly. It shares an overlap in clinical features with two recessive cancer susceptibility syndromes, Nijmegen breakage syndrome and Fanconi anemia (FA) \[[@B16],[@B17]\]. Interestingly, the gene that is defective in two FA complementation groups, namely FA-B and FA-D1, has been identified as *BRCA2*-- a major breast cancer susceptibility gene \[[@B18],[@B19]\]. In addition, carriers of the Nijmegen breakage syndrome Slavic founder mutation appear to be at increased risk for breast cancer \[[@B20]\]. Thus far, predisposition to cancer has not been reported in patients with Seckel syndrome. However, various cell lines in which *ATR*has been inactivated exhibit genetic instability, and this may predict proneness to cancer \[[@B17]\].

Based on this, we wanted to determine whether *ATR*germline mutations are involved in susceptibility to breast and/or ovarian cancer, and conducted a mutation analysis of all 47 coding exons and exon--intron boundaries in the affected index cases in 126 families.

Materials and methods
=====================

Subjects
--------

The index cases of 126 breast and/or ovarian cancer families originating from northern Finland were screened for *ATR*germline mutations. Of the studied families, 94 were affected by breast, 29 by breast/ovarian and three by ovarian cancer. All index cases had been diagnosed with either breast or ovarian cancer. 75 of the families were classified as high-risk families and were defined as follows: three or more cases of breast and/or ovarian cancer in first- or second-degree relatives; or two cases of breast and/or ovarian cancer in first- or second-degree relatives, of which at least one had early disease onset (age ≤35 years), bilateral disease, or multiple primary tumours. Most of the high-risk families contained three or more cancer cases. The remaining 51 families contained two cases of breast and/or ovarian cancer in first- or second-degree relatives and were considered to be at moderate disease risk. All of the high-risk families had previously been screened for germline mutations in *BRCA1*, *BRCA2*, *CHK2*and *TP53*\[[@B21]-[@B23]\] and 10 families were known to have disease-related mutations in *BRCA1*or *BRCA2*. The frequencies of all observed germline variants were assessed in either 100 or 300 control individuals, who were anonymous cancer-free blood donors originating from the same geographical region as the studied families.

All patients gave informed consent for acquisition of pedigree data and blood specimens for use in a study on cancer susceptibility gene mutations. Approval to perform the study was obtained from the Ethical Board of the Northern Ostrobothnia Health Care District and the Finnish Ministry of Social Affairs and Health.

Mutation analysis
-----------------

DNA was extracted from blood lymphocytes using either the standard phenol--chloroform protocol or the Puregene D-50K purification kit (Gentra, Minneapolis, MN, USA). Screening of the protein encoding and exon--intron boundary regions of *ATR*was done by conformation sensitive gel electrophoresis (CSGE), which is a cost-efficient way to scan for mutations with high detection sensitivity and specificity \[[@B24],[@B25]\], or by direct sequencing. Sequencing analysis was performed using the Li-Cor IR^2^4200-S DNA Analysis system (Li-Cor Inc., Lincoln, NE, USA) and the SequiTherm EXCEL™II DNA Sequencing Kit-LC (Epicentre Technologies, Madison, WI, USA). Oligonucleotides for CSGE and sequencing (Table [1](#T1){ref-type="table"}) were designed using Primer3 software \[[@B26]\], utilizing sequence information obtained from public databases. Polymerase chain reaction conditions for CSGE and sequencing are available upon request.

Statistical analyses
--------------------

Fisher\'s exact test or χ^2^test was used to determine statistical significance (SPSS version 12.0 for Windows; SPSS Inc., Chicago, IL, USA). All *P*values were two sided.

Results
=======

Mutation analysis revealed several alterations in the *ATR*gene. Altogether, 23 nucleotide substitutions were observed: 17 in the exon and six in the intron regions (Tables [2](#T2){ref-type="table"} and [3](#T3){ref-type="table"}). Eleven of the exonic changes resulted in amino acid substitutions, eight of which were novel and three were polymorphisms reported in the single nucleotide polymorphism database \[[@B27]\]. The location of the amino acid changes is summarized in Fig. [1](#F1){ref-type="fig"}. All observed nucleotide alterations were assessed for possible effects on splicing consensus sequences \[[@B28]\], and the coding sequence variants were tested using the ESEfinder program \[[@B29]\] to identify those that reduced the exonic splicing enhancer (ESE) score below the calculated threshold.

Of the observed amino acid substitutions, four were located in known functional sites: Arg2008Leu and Tyr2132Asp to the FAT (FRAP/ATM/TRRAP) domain, and Arg2425Gln and Ile2435Val to the PI3Kc (phosphoinositide 3-kinase related catalytic) domain. The novel Arg2008Leu, Tyr2132Asp and Ile2435Val alterations occurred in one index case each. Interestingly, Arg2008Leu appeared to have an effect on two ESEs (SF2/ASF and SC35), as predicted by the ESEfinder program.

Arg2008Leu was identified in a patient with both ovarian and colon cancer at age 51 years, and her sister, diagnosed with breast cancer at age 72 years, was found to be a carrier. However, because Arg2008Leu, Tyr2132Asp or Ile2435Val carriers were also observed in control individuals, these changes were all classified as rare variants. Arg2425Gln is a common polymorphism described in the single nucleotide polymorphism database, and its frequency was similar in cases (27.8%) and controls (24.0%).

The rest of the amino acid substitutions were all located outside the kinase and FAT/FATC domains, although two of these, Glu254Gly and Ser1142Gly, were absent from the tested controls. Glu254Gly affects a nonconserved residue, and was seen in one patient diagnosed with breast cancer at age 37 years. However, her maternal cousin, with bilateral breast cancer at ages 45 and 55 years, was not a carrier. The other change, Ser1142Gly, affects a residue that is also conserved in ATR of *Xenopus laevis*and in mei41 of *Drosophila melanogaster*\[[@B30]\]. Ser1142Gly was seen in two index cases with breast cancer (2/126; *P*= 0.09). In the first family the patient was diagnosed at age 64 years. Two of her daughters had breast cancer at ages 49 and 40 years, but both tested negative for Ser1142Gly. Also, two sisters of the index had breast cancer at unknown ages, but no samples were available for mutation testing. In the second family the index patient was diagnosed at age 59 years, but her sister, who had breast cancer at age 45 years, was not a carrier. Neither Glu254Gly nor Ser1142Gly had an affect on splicing consensus sequences or ESEs.

Of the six intronic changes, two were absent from the tested control individuals: IVS24-48G\>A was observed in the index case of three families (3/126; *P*= 0.03) and IVS26+15C\>T was observed in one case. Unfortunately, only one additional DNA sample from an affected relative was available for mutation testing, and this maternal cousin of the index case proved negative for IVS24-48G\>A. Also IVS31-74G\>A was found more frequently in cases (8.7%) than in control individuals (4.3%), but the difference was only marginally significant (odds ratio 2.1, 95% confidence interval 0.92--4.85; *P*= 0.07). None of the observed intron changes had an affect on consensus splice sites.

Discussion
==========

ATR plays a critical role in the maintenance of genomic integrity. A number of tumour suppressor proteins act downstream of ATR, placing it high in the DNA damage response cascade \[[@B5]\]. Impaired ATR signalling has been shown to result in Seckel syndrome, but thus far predisposition to cancer in these patients has not been reported \[[@B16]\]. Nevertheless, cell lines with inactivated *ATR*exhibit genetic instability, which may suggest proneness to cancer \[[@B17]\].

To investigate the possible role played by *ATR*germline mutations in hereditary predisposition to breast and ovarian cancer, the whole coding region of the gene was screened for mutations in the index cases from 126 families. We found a number of novel sequence variants, but we did not identify any clearly pathogenic alterations. Only two of the observed missense changes, Glu254Gly and Ser1142Gly, were absent from control individuals. However, because the variants did not segregate with the cancer phenotype in these families, they are unlikely to be important cancer susceptibility alleles. Evaluation of the intronic variants IVS24-48G\>A and IVS26+15C\>T is more difficult because only one additional DNA sample was available for mutation testing, but neither had any affect on consensus splicing sequences. The possible association of the identified rare variants with predisposition to cancer must be demonstrated by more extensive case--control studies.

The performed mutation analysis is to our knowledge the first to investigate the possible association of germline *ATR*mutations with cancer predisposition. However, the results of the study suggest that *ATR*is not involved in hereditary susceptibility to breast and ovarian cancer. The lack of deleterious germline mutations could reflect a fundamental role for ATR in cell viability, including DNA replication \[[@B5]\]. Nonetheless, because *ATR*changes have thus far been reported only in gastric and endometrial tumours exhibiting microsatellite instability, it is also possible that breast and/or ovarian cancer is not the primary cancer phenotype associated with germline mutations in this gene \[[@B13],[@B14]\]. These findings need confirmation by other studies.

Conclusion
==========

Based on its central role in the maintenance of genomic integrity, we hypothesized that germline mutations in *ATR*may account for some breast and/or ovarian cancer families. However, analysis of 126 index cases suggests that *ATR*mutations do not play a major role in hereditary susceptibility to these cancers.
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###### 

Primers used to amplify exons and splice junctions of *ATR*

  Exon    Forward^a^                       Reverse
  ------- -------------------------------- --------------------------------
  1       ccgggtcctatgcagaaaag             aggggagagcacgtgaaac
  2       cattgacactgaacacatttgatg         tctaaaactacatggagaaaatgct
  3       ggcccacagtctggtttct              gtaatatttcagaagagcagtaaaagg
  4a      tcgtcaaggatttagcaaatga           acgagtaagaaccattaataaagtgac
  4b      atgtgatgggtcatgctgtg             gctcttcatagagtttcaattggtc
  4c      tccaaaaattaaatccctagcaa          tctcacatagaccttcctgacttg
  4d      aaactctgtgtcatgtttgaagac         gccagactacactatgaaaatcatta
  5       cattcttgctgcctatgaataa           aaatcaaagcacttaactaaagctga
  6       tctaaatatgtttcatgttttaaccaa      tgagtcaagtgaataatgagtaaaca
  7       tggctttactacaattttatgtttgac      cacttaggcttcaggcaaaa
  8^b^    tttaaaagagatatgattaaggaaaag      cacacattcttgtgagcactt
  9       aaatgtattttaagtgttacttgactttt    aaccctgcatacatagccaga
  10      gtcccaaattaagcaagactattt         caaggcttcagtctaattcttttac
  11      tcatggcatattatttgttgac           gaacaataaaattaactggttaaagaa
  12      gaggttgataatttttgtttttaacat      ccatttttaacagcaagcaaa
  13      tgagtcaacatgaatttatttgtagat      aaagaaaagcaagcaaaataaaac
  14      ctctatggtggcttaaaaagtattagt      caaagtcaaaatctagaatggaatg
  15      ctccaaatatgtgtggcattt            accctctttcctagaagaatgttac
  16      ctcctgatgtactaatagcatgttaaa      tgaccaaaaatatgatttcttcaat
  17      gcttttggagaaacttaattaacca        tgtttgtagctagatgcagaattt
  18^b^   tgtccttagggctcatctgc             tgaacccaatttccctcaaa
  19      gctgccttttaatctattgtttg          cattaccatcagtaattttgagacat
  20      ggccttagtttcaacttttactttaca      caggaattagctatcagaataggact
  21      gagaattcaggcctttggaa             aatgtcattttgtcatcttttcttt
  22      aactcatcaaaaactagctgaaaaa        ggataagctgaatagttctttgtaaat
  23      ccatggaaaaagcagtacacc            aaaacaaaaaggagtttcacaagt
  24      gcataaataaagcgaagtgcaa           ggccaaaaaaatcgcatta
  25      agtcaactgaaggagttgctg            ttgtgtgtgctaggcattcag
  26      ttatctcacatgctactctttgaca        catttcctactaataggtagcctttc
  27      ttagaatggttagctttagatgtcata      agaactgataaagggaagagctaa
  28      caattgttctgttgttagttacattct      gcatagcatataaaacattcaataaaa
  29      aaacaggtggttttatagttttatttc      aaggtttccagagttcctattca
  30      aagggcaataaggtaaatagtaat         aaattacccaattcactaactaaaaa
  31      gaacaaaatacaatataatgcaaattcaa    accgcacccatcctaaaact
  32      ttgatatttcagctgaccattttatc       ccaaactcactatcaattatttactcaaa
  33      caactgtgtattttaaattctttatttctg   cacccccaaataatatccaa
  34^b^   attgggaacagaggctttca             gacatttccctggccattac
  35      caaaaacataatgaactaatacttttgc     catgtgctttgccatatagactt
  36      tcacatacttttgatccctaatca         acctagaatatgctaagacatgtga
  37      tttttgtgaaaacggtatgtgg           agactgtccagccaaatctga
  38      tgtgaaatgaactgatatactgattttt     cgccctggaacttgtatcta
  39      aactctcatcatgaatactttttaagtt     aaaaactgctttattaagacaaatcat
  40      ttgtaaaagtgaaatttttgttatagtgg    ttgtgaaatacactttttatcttaatttga
  41      tttacacagaaatttttggcccta         caactctgaaataaaagcaatctgg
  42      tttggttatgaaatgaacaatcttt        aggaagggatggaaacactt
  43      agtagatgtttcttgtccaattttaac      catatgaggccaatataaatctaaaa
  44      gttgttatggttgaatgtttattttta      caaggaagatacagttgttgagaa
  45      tggacatgaagttctttgagtaaa         caaacatatgtaggggccaat
  46      agcttctcatccttcacttaaa           aactatagctgcatatcaagttca
  47a     gggtattggtcagtaaaatggta          ccacagattcataccaaatgc
  47b     gaaggacatgtgcattaccttatac        cttgcttgtttcttgcaaatatag

^a^All primer sequences are shown in the 5\' to 3\' direction. ^b^The amplified fragment was analyzed by direct sequencing.

###### 

Observed sequence variation in the protein-encoding regions of *ATR*

  Exon   Nucleotide change   Effect on protein   Carrier frequency   *P*               Status^a^   
  ------ ------------------- ------------------- ------------------- ----------------- ----------- ----------
  3      268C\>T             His90Tyr            12.7% (16/126)      10.3% (31/300)    0.50        Novel
  4      632T\>C             Met211Thr           54.0% (68/126)      47.3% (142/300)   0.20        Reported
         761A\>G             Glu254Gly           0.8% (1/126)        \- (0/300)        0.30        Novel
         891G\>C             Lys297Asn           1.6% (2/126)        2.3% (7/300)      1.00        Reported
                                                                                                   
  8      1776T\>A            Gly592Gly           50.8% (64/126)      41.0% (41/100)    0.18        Reported
         1815T\>C            Asp605Asp           46.8% (59/126)      49.0% (49/100)    0.79        Reported
  14     2946C\>T            Phe982Phe           0.8% (1/126)        2.0% (6/300)      0.68        Novel
  17     3424A\>G            Ser1142Gly          1.6% (2/126)        \- (0/300)        0.09        Novel
  21     3893A\>T            Asp1297Val          0.8% (1/126)        1.0% (3/300)      1.00        Novel
  26     4576A\>G            Ile1526Val          4.0% (5/126)        2.0% (6/300)      0.31        Novel
  30     5208T\>C            Tyr1736Tyr          23.8% (30/126)      37.0% (37/100)    0.03        Reported
  32     5459T\>C            Tyr1820Tyr          26.2% (33/126)      31.0% (31/100)    0.43        Reported
  35     6023G\>T            Arg2008Leu          0.8% (1/ 126)       0.3% (1/300)      0.51        Novel
  38     6394T\>G            Tyr2132Asp          0.8% (1/126)        0.3% (1/300)      0.51        Novel
  43     7274G\>A            Arg2425Gln          27.8% (35/126)      24.0% (72/300)    0.46        Reported
         7303A\>G            Ile2435Val          0.8% (1/126)        0.3% (1/300)      0.51        Novel
  47     7875A\>G            Gln2625Gln          27.0% (34/126)      35.0% (35/100)    0.19        Reported

^a^Novel or reported in the National Center for Biotechnology Information single nucleotide polymorphism database <http://www.ncbi.nlm.nih.gov/SNP/>.

###### 

Observed sequence variation in the intron regions of *ATR*

  Location   Nucleotide change   Carrier frequency   *P*             Status^a^   
  ---------- ------------------- ------------------- --------------- ----------- -------
  IVS2-51    A\>T                9.5% (12/126)       9.0% (9/100)    0.89        Novel
  IVS16-26   T\>A                2.4% (3/126)        4.3% (13/300)   0.41        Novel
  IVS18-22   G\>C                4.8 % (6/126)       4.0% (12/300)   0.72        Novel
  IVS24-48   G\>A                2.4% (3/126)        \- (0/300)      0.03        Novel
  IVS26+15   C\>T                0.8% (1 /126)       \- (0/300)      0.30        Novel
  IVS31-74   G\>A                8.7% (11/126)       4.3% (13/300)   0.07        Novel

^a^Novel or reported in the National Center for Biotechnology Information single nucleotide polymorphism database <http://www.ncbi.nlm.nih.gov/SNP/>.
